Sökresultat - "Fornecker, Luc-Mathieu"

Outcomes of patients with Hodgkin lymphoma receiving Brentuximab Vedotin (BV) as maintenance therapy after ASCT according to previous exposure to BV. A retrospective analysis of the EBMT Lymphoma Working Party in collaboration with GELTAMO, FIL, LYSA, and Turkish Lymphoma Group

Martínez, Carmen^{Aff1, IDs41409025025684_cor1}, Khvedelidze, Irma, Fekom, Mathilde, Deau Fischer, Benedicte^{Aff3, Aff4}, Marouf, Amira, Ghesquières, Hervé, Fornecker, Luc-Mathieu, Merli, Francesco, Stefani, Piero Maria, Massaro, Fulvio, Botto, Barbara, Ferhanoğlu, Burhan, Akay, Olga Meltem, Özbalak, Murat, Espeso de Haro, Manuel, Romero, Samuel, Galimard, Jaques-Emmanuel, Glass, Bertram, Bazarbachi, Ali, Sureda, Anna

Blinatumomab after R-CHOP bridging therapy for patients with Richter transformation: a phase 2 multicentre trial

Guièze, Romain^{Aff1, Aff2, IDs41467024512642_cor1}, Ysebaert, Loïc, Roos-Weil, Damien, Fornecker, Luc-Mathieu, Ferrant, Emmanuelle, Molina, Lysiane, Aurran, Thérèse, Clavert, Aline, de Guibert, Sophie, Michallet, Anne-Sophie, Saad, Alain, Drénou, Bernard, Quittet, Philippe, Hivert, Bénédicte, Laribi, Kamel, Gay, Julie, Quinquenel, Anne, Broseus, Julien^{Aff19, Aff20}, Rouille, Valérie, Schwartz, David, Magnin, Benoit, Lazarian, Grégory, Véronèse, Lauren^{Aff2, Aff24}, de Antonio, Marie, Laurent, Camille, Tournilhac, Olivier^{Aff1, Aff2}, Pereira, Bruno, Feugier, Pierre^{Aff20, Aff27}

Classic Hodgkin Lymphoma: The LYSA pragmatic guidelines

Rossi, Cédric, Manson, Guillaume, Marouf, Amira, Cabannes-Hamy, Aurélie, Nicolas-Virelizier, Emmanuelle, Maerevoet, Marie, Alcantara, Marion, Molina, Lysiane, Ceraulo, Antony, Poirée, Marilyne, Galtier, Jean, Diop, Nadia, Delette, Caroline, Segot, Amandine, Dubois, Sydney, Waultier, Agathe, Bernard, Sophie, Noël, Robin, Guidez, Stéphanie, Kohn, Milena, Bailly, Sébastien, Moatti, Hannah, Touati, Mohamed, Renaud, Loïc, Kanoun, Salim, Cottereau, Anne-Ségolène, Kirova, Youlia, Peignaux, Karine, Dourthe, Marie-Emilie, Simonin, Mathieu, Leblanc, Thierry, Quéro, Laurent, Krzisch, Daphné, Duléry, Remy, Grenier, Adrien, Gastinne, Thomas, Casasnovas, Olivier, Gallamini, Andrea, André, Marc, Morschhauser, Franck, Deau, Bénédicte, Fornecker, Luc-Mathieu, Ghesquières, Hervé

A fixed-duration immunochemotherapy approach in CLL: 5.5-year results from the phase 2 ICLL-07 FILO trial

Michallet, Anne-Sophie, Letestu, Rémi, Le Garff-Tavernier, Magali, Campos, Lydia, Ticchioni, Michel, Dilhuydy, Marie-Sarah, Morisset, Stephane, Rouille, Valérie, Mahé, Béatrice, Laribi, Kamel, Villemagne, Bruno, Ferrant, Emmanuelle, Tournilhac, Olivier, Delmer, Alain, Molina, Lysiane, Leblond, Véronique, Tomowiak, Cécile, de Guibert, Sophie, Orsini-Piocelle, Frederique, Banos, Anne, Carassou, Philippe, Cartron, Guillaume, Fornecker, Luc Mathieu, Ysebaert, Loic, Dartigeas, Caroline, Truchan-Graczyk, Margot, Vilque, Jean-Pierre, Schleinitz, Thérèse Aurran, Cymbalista, Florence, Leprêtre, Stéphane, Lévy, Vincent, Nguyen-Khac, Florence, Feugier, Pierre

Obinutuzumab and ibrutinib induction therapy followed by a minimal residual disease-driven strategy in patients with chronic lymphocytic leukaemia (ICLL07 FILO): a single-arm, multicentre, phase 2 trial

Michallet, Anne-Sophie ^*, Dilhuydy, Marie-Sarah, Subtil, Fabien, Rouille, Valerie, Mahe, Beatrice, Laribi, Kamel, Villemagne, Bruno, Salles, Gilles, Tournilhac, Olivier, Delmer, Alain, Portois, Christelle, Pegourie, Brigitte, Leblond, Veronique, Tomowiak, Cecile, de Guibert, Sophie, Orsini, Frederique, Banos, Anne, Carassou, Philippe, Cartron, Guillaume, Fornecker, Luc Mathieu, Ysebaert, Loic, Dartigeas, Caroline, Truchan Graczyk, Malgorzata, Vilque, Jean P, Aurran, Thérèse, Cymbalista, Florence, Lepretre, Stéphane, Lévy, Vincent, Nguyen-Khac, Florence, Le Garff-Tavernier, Magali, Aanei, Carmen, Ticchioni, Michel, Letestu, Rémi, Feugier, Pierre

Rituximab and dose-dense chemotherapy for adults with Burkitt's lymphoma: a randomised, controlled, open-label, phase 3 trial

Ribrag, Vincent, Koscielny, Serge, Bosq, Jacques, Leguay, Thibaut, Casasnovas, Olivier, Fornecker, Luc-Mathieu, Recher, Christian, Ghesquieres, Hervé, Morschhauser, Franck, Girault, Stéphane, Gouill, Steven Le, Ojeda-Uribe, Mario, Mariette, Clara, Cornillon, Jerome, Cartron, Guillaume, Verge, Veronique, Chassagne-Clément, Catherine, Dombret, Hervé, Coiffier, Bertrand, Lamy, Thierry, Tilly, Hervé, Salles, Gilles

A Fixed-Duration Immunochemotherapy Approach Combined with Ibrutinib in CLL Produces Deep and Sustained MRD Responses: 5.5-Year Results from the Icll-07 Filo Trial

Michallet, Anne-Sophie ^*, Letestu, Rémi ^*, Le Garff-Tavernier, Magali ^*, Aanaei, Carmen ^*, Ticchioni, Michel ^*, Dilhuydy, Marie-Sarah ^*, Morisset, Stephane ^*, Rouille, Valérie ^*, Mahé, Béatrice ^*, Laribi, Kamel ^*, Villemagne, Bruno ^*, Ferrant, Emmanuelle ^*, Tournilhac, Olivier ^*, Delmer, Alain, Portois, Christelle ^*, Molina, Lysiane ^*, Leblond, Véronique, Tomowiak, Cécile ^*, de Guibert, Sophie ^*, Orsini, Frederique ^*, Banos, Anne ^*, Carassou, Philippe ^*, Cartron, Guillaume ^*, Fornecker, Luc Mathieu ^*, Ysebaert, Loic ^*, Dartigeas, Caroline ^*, Truchan, Margot ^*, Vilque, Jean-Pierre ^*, Aurran Schleinitz, Therese ^*, Florence, Cymbalista ^*, Leprêtre, Stéphane ^*, Lévy, Vincent ^*, Nguyen Khac, Florence ^*, Feugier, Pierre ^*

Preliminary Results of the Filo Phase 2 Trial for Untreated Fit Patients with Intermediate Risk Chronic Lymphocytic Leukemia Comparing Ibrutinib Plus Venetoclax (IV) Versus FCR: Results of the Month 15 MRD Evaluation

Quinquenel, Anne ^*, Letestu, Rémi ^*, Le Garff-Tavernier, Magali ^*, Subtil, Fabien ^*, Aurran-Schleinitz, Therese ^*, Laribi, Kamel ^*, Cymbalista, Florence ^*, Levy, Vincent ^*, Simon, Laurence ^*, Roos-Weil, Damien ^*, Leblond, Véronique ^*, Dilhuydy, Marie-Sarah ^*, Dartigeas, Caroline ^*, Tomowiak, Cecile ^*, Guieze, Romain ^*, Tournilhac, Olivier ^*, Ferrant, Emmanuelle ^*, de Guibert, Sophie ^*, Feugier, Pierre ^*, Merabet, Fatiha ^*, Lepretre, Stephane ^*, Carassou, Philippe ^*, Gay, Julie ^*, Hivert, Bénédicte ^*, Fornecker, Luc Mathieu ^*, Dupuis, Jehan ^*, Molina, Lysiane ^*, Villemagne, Bruno ^*, Cartron, Guillaume ^*, Drenou, Bernard ^*, Mahé, Béatrice ^*, Benbrahim, Omar ^*, Cahu, Xavier ^*, Portois, Christelle ^*, Ysebaert, Loic ^*, Nguyen Khac, Florence ^*, Rouille, Valérie ^*, Delmer, Alain, Michallet, Anne-Sophie ^*

Denna resultat visas inte till gäster.
Logga in för full Login for full tillgång.

Denna resultat visas inte till gäster.
Logga in för full Login for full tillgång.

Denna resultat visas inte till gäster.
Logga in för full Login for full tillgång.

Denna resultat visas inte till gäster.
Logga in för full Login for full tillgång.

Denna resultat visas inte till gäster.
Logga in för full Login for full tillgång.

Combined Treatment with Ibrutinib and Anti-CD38 Monoclonal Antibody Daratumumab in Relapsed/Refractory Chronic Lymphocytic Leukemia with TP53 Aberrations: Results of the Filo Phase II Study IDA53

Aurran-Schleinitz, Therese ^*, Tomowiak, Cécile ^*, Roos-Weil, Damien ^*, Ferrant, Emmanuelle ^*, Mahé, Béatrice ^*, Molina, Lysiane ^*, Ysebaert, Loic ^*, Fornecker, Luc Mathieu ^*, Michallet, Anne-Sophie ^*, Levy, Vincent ^*, Guieze, Romain ^*, Delmer, Alain

Denna resultat visas inte till gäster.
Logga in för full Login for full tillgång.

Denna resultat visas inte till gäster.
Logga in för full Login for full tillgång.

Denna resultat visas inte till gäster.
Logga in för full Login for full tillgång.

Denna resultat visas inte till gäster.
Logga in för full Login for full tillgång.

Denna resultat visas inte till gäster.
Logga in för full Login for full tillgång.

Denna resultat visas inte till gäster.
Logga in för full Login for full tillgång.